Emmanuelle Passegué, PhD
- Professor of Genetics & Development
- Director, Columbia Stem Cell Initiative
Emmanuelle Passegué, Ph.D., is the Alumni Professor of Genetics and Development (in Rehabilitation and Regenerative Medicine) and the Director of the Columbia Stem Cell Initiative at Columbia University Medical Center (CUMC). Dr. Passegué received her Ph.D. from the University Paris XI (France), and trained with Dr. Erwin Wagner (Institute for Molecular pathology, Vienna, Austria) and Dr. Irv Weissman (Stanford University, USA) before joining the University of California San Francisco (UCSF) in 2005. Dr. Passegué was a Professor of Medicine in the Hematology/Oncology Division and the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at UCSF until 2016 before joining CUMC in January 2017.
Credentials & Experience
Honors & Awards
2017 - NHLBI Outstanding Investigator Award
2014 - Glenn Award for Research on the Biological Mechanisms of Aging
2014 - McCulloch and Till Lectureship Award (ISEH)
2012 - Leukemia and Lymphoma Society (LLS) Scholar Award
2009 - California Institute of Regenerative Medicine (CIRM) New Faculty Award
2008 - Rita Allen Scholar Award
2007 - American Society of Hematology (ASH) Scholar Award
Hematopoiesis & Hematopoietic Stem Cell Biology
Our laboratory studies how hematopoietic stem cells (HSC) regulate blood production during the lifetime of an ever-changing organism. This fundamental question is central to tissue development, maintenance and regeneration, and has implications for every aspect of adult physiology ranging from response to stress, development of diseases, and biology of aging. We are interested in identifying the mechanisms that control HSC activity in normal and a range of deregulated conditions, with the goal of identifying affected genes and pathways that could be used to develop new therapies to treat human myeloid malignancies and help combat physiological aging. Towards this end, we are employing a variety of cross-disciplinary approaches using mouse models and human samples.
- Stem cells in tissue homeostasis and aging
- Hematopoietic stem cell biology
- Myeloid malignancies
EMERGENCY MYELOPOIESIS PATHWAYS IN THE CONTROL OF BLOOD PRODUCTION (Federal Gov)
Apr 1 2017 - Mar 31 2024
AUTOPHAGY AND HEMATOPOIETIC STEM CELL FUNCTION IN AGING AND LEUKEMIA (Private)
Jul 1 2019 - Jun 30 2021
LEUKEMIA & LYMPHOMA SOCIETY CAREER DEVELOPMENT PROGRAM (Private)
Jul 1 2017 - Jun 30 2019
ROLE OF AUTOPHAGY IN NORMAL AND TRANSFORMED HEMATOPOIETIC STEM CELLS (Federal Gov)
Apr 1 2017 - Mar 31 2019
PLATELET AND MEGAKARYOCYTE BIOLOGY IN THE NORMAL AND INJURED LUNG (Federal Gov)
Jul 1 2017 - Apr 30 2018
LEUKEMIA AND LYMPHOMA SOCIETY GRANT AGREEMENT (Private)
Jan 1 2017 - Jun 30 2017
Hérault A, Binnewies M, Leong S, Calero-Nieto FJ, Zhang SY, Kang Y-A, Wang X, Pietras E, Chu SH, Barry-Holson K, Armstrong S, Göttgens B, Passegué E. Myeloid progenitor cluster formation drives emergency and leukemic myelopoiesis. Nature, 544:53-58, 2017.
Ho TT, Warr MR, Adelman E, Lansinger O, Flach J, Verovskaya E, Figueroa ME, Passegué E. Autophagy maintains metabolism and functional activity of a subset of aged hematopoietic stem cells. Nature, 543:205-210, 2017.
Pietras M, Mirantes-Barbeito C, Fong S, Löeffler D, Kovtonyuk LV, Zhang SY, Lakshminarasimhan R, Chin CP, Techner J-M, Will B, Nerlov C, Steidl U, Manz MG, Schroeder T, Passegué E. Interleukin-1 drives hematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nat Cell Biol, 18:607-618, 2016.
Pietras E*, Reynaud D*, Carlin D, Calero-Nieto FJ, Kang YA, Leavitt AD, Stuart JM, Gottgens B, Passegué E. Functionally distinct subsets of lineage-biased multipotent progenitors control blood production in normal and regenerative conditions. Cell Stem Cell, 17:35-46, 2015. (*equal contribution)
Flach J, Bakker ST, Mohrin M, Conroy PC, Pietras EM, Reynaud D, Alvarez S, Diolaiti ME, Ugarte F, Forsberg EC, Le Beau MM, Stohr BA, Méndez J, Morrison CG, Passegué E. Replication stress is a potent driver of functional decline in aging hematopoietic stem cells. Nature, 512:198-202, 2014.
Pietras EM, Lakshminarasimhan R, Techner JM, Fong S, Flach J, Binnewies M, Passegué E. Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J Exp Med, 211:245-262, 2014.
Schepers K, Pietras EM, Reynaud D, Flach J, Binnewies M, Garg T, Wagers AJ, Hsiao EC, Passegué E. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell, 13:285-299, 2013.
Warr MR, Binnewies M, Flach J, Reynaud D, Garg T, Malhotra R, Debnath J, Passegué E. FOXO3A directs a protective autophagy program in haematopoietic stem cells. Nature, 494:323-327, 2013.
Reynaud D, Pietras EM, Barry-Holson K, Mir A, Binnewies M, Jeanne M, Sala-Torra O, Radich JP, Passegué E. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell, 20:661-673, 2011.
Mohrin M, Bourke E, Alexander D, Warr M, Barry-Holson K, LeBeau M, Morrison CG, Passegué E. Hematopoietic stem cell quiescence promotes error prone DNA repair and mutagenesis. Cell Stem Cell, 7:174-485, 2010.
Santaguida M, Schepers K, King B, Sabnis AJ, Forsberg EC, Attema JL, Braun BS, Passegué E. JunB protects against myeloid malignancies by limiting hematopoietic stem cell proliferation and differentiation without affecting self-renewal. Cancer Cell, 15:341-352, 2009.